MAIN RESULTS:
Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease
Circulation. 2022;146:1109–1119.
MAIN RESULTS PRESENTATIONS
FOURIER Open Label Extension Primary Results (O’Donoghue, ESC 2022)
PRESENTATIONS
Association Between Achieved LDL-Cholesterol and Long-term Cardiovascular and Safety Outcomes – An Analysis of the FOURIER and FOURIER-OLE Studies (Gaba, AHA 2022)
Reduction in Total CV Events with the PCSK9 Inhibitor Evolocumab in Patients with Cardiovascular Disease in the Combined FOURIER and FOURIER OLE Studies (Murphy, ACC 2023)